Navigation Links
Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting
Date:12/10/2007

* Recommended Phase II Dose of MGCD0103 Determined as 90 mg * 53% of Patients Treated with 90 mg Dose Achieved a Clinical Response * Patients with Responses Experienced a 66% Reduction in the Risk of Death

Compared to Non-responders

ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc (TSX: MYG) today announced maturing data from the Phase 1/2 study investigating the combined use of MGCD0103, a novel, isotype-selective histone deacetylase (HDAC) inhibitor, and Vidaza(R) (azacitidine for injection) in patients with myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML). A 53 percent response rate (n=19) was demonstrated at the 90 mg dose with a median time to response of less than two months. The overall results indicate a 36 percent response rate for patients evaluated at all doses (n=52 evaluable patients) in this Phase 1/2 study. The data were presented in an oral presentation today at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Atlanta.

"This study demonstrates the progress Pharmion has made in advancing the clinical development of these therapies in treating MDS and AML, and reinforces Pharmion's standing as a leader in epigenetic therapy," said Patrick J. Mahaffy, president and chief executive officer of Pharmion. "Together, Vidaza and MGCD0103 showcase Pharmion's highly complementary clinical hematology and oncology portfolio."

"This study and data from our other clinical trials continue to demonstrate MGCD0103's potential utility when used in combination or as a single-agent," said Donald F. Corcoran, President and Chief Executive Officer of MethylGene. "The results of this stu
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
2. Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting
3. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
4. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
5. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
6. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
7. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
8. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
9. AtriCure to Present at Roth Capital Partners 2007 New York Conference
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. MDS to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... Alcohol Awareness Month , The National Council ... sponsoring Alcohol Awareness Month every April since 1987. ... understating of alcohol-related issues. During the month of ... and alcoholism. , For the Health of It: Early ... for Alcohol Awareness Month. During April, focus is ...
(Date:4/1/2015)... Royal River Natural Foods, a locally-owned independent natural health store ... amino acid creatine, which athletes typically use to build strength ... The report is part of the April 2015 ... Royal River Natural Foods publishes each month as a free ... in nutrition science. Also in the April issue, vitamin D ...
(Date:4/1/2015)... One year ago today, the USO cut the ribbon on ... States and changed the landscape on Naval Support Activity Bethesda ... more than 100,000 troops and military families in the last ... injured and their families, proving to be a valuable resource ... the country. After opening its doors on the campus that ...
(Date:4/1/2015)... Bird B Gone, the leader in ... now offers a complete line of Bird Netting ... netting products quickly, safely and efficiently. , Having the ... bird netting installation. It’s important to determine exactly what ... a project. This includes deciding whether to use all ...
(Date:4/1/2015)... CA, March 24, 2015 (PRWEB) April 01, 2015 ... by many, the most extreme jungle adventure you could ever ... many as 23 days. Endorsed by the Philippine Department of ... people have visited the rainforest, but very few people have ... Bergman, Chief Adventure Officer. , Armed with nothing more than ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Releases Guide to Handling Alcoholism in the Family for Alcohol Awareness Month 2Health News:Narconon Arrowhead Releases Guide to Handling Alcoholism in the Family for Alcohol Awareness Month 3Health News:New Study Finds Strength-Building Supplement Improves Circulation, Retailer Reports 2Health News:USO’s Warrior and Family Center at Bethesda Marks First Anniversary and More than 100,000 Servicemen and Women Served 2Health News:USO’s Warrior and Family Center at Bethesda Marks First Anniversary and More than 100,000 Servicemen and Women Served 3Health News:USO’s Warrior and Family Center at Bethesda Marks First Anniversary and More than 100,000 Servicemen and Women Served 4Health News:USO’s Warrior and Family Center at Bethesda Marks First Anniversary and More than 100,000 Servicemen and Women Served 5Health News:Bird B Gone Now Carries Complete Bird Netting Hardware 2Health News:Bird B Gone Now Carries Complete Bird Netting Hardware 3
... ,In the 30 years since the first reported cases ... have made extraordinary advances in understanding, treating and preventing ... the National Institute of Allergy and Infectious Diseases (NIAID), ... build on those successes to control and, ultimately, end ...
... New England Journal of Medicine , physicians and ... successful treatment of three young children who were suffering ... with enterohemorrhagic Escherichia coli (EHEC). The infections ... the current wave of infections that have already claimed ...
... a world-leading publisher of scientific, technical and medical information ... of a new journal, International Journal of Paleopathology ... quarterly, the first issue of the journal is now ... copies of the first issue will be available at ...
... Researchers at Children,s Hospital Boston and Google.org have found web-based ... early detection and monitoring of outbreaks of dengue, an emerging ... search data allows the capture of disease-related queries in near ... more than 100 countries affected by dengue respond more quickly ...
... , MONDAY, May 30 (HealthDay News) -- Although stress ... person,s risk for developing the disease in the first place, ... than 100,000 nurses each, ranging in age from 24 to ... Those examined were asked about their levels of stress both ...
... ST. PAUL, Minn. Contrary to earlier reports, a new ... person,s risk of developing multiple sclerosis (MS). The research is ... Neurology , the medical journal of the American Academy of ... have been shown to increase the risk of MS episodes, ...
Cached Medicine News:Health News:Antibodies successful in the treatment of the hemolytic-uremic syndrome from EHEC 2Health News:Elsevier launches new journal: International Journal of Paleopathology 2Health News:Searching the web for dengue 2
(Date:4/1/2015)... , April 1, 2015 International Isotopes Inc. ... fiscal year ended December 31, 2014.  The Company reports ... net loss, and positive cash flow for the year ... revenue in 2014 was approximately $7.5 million compared to ... of approximately 10%.  With the exception of the radiological ...
(Date:4/1/2015)... , April 1, 2015 ... ), a clinical-stage pharmaceutical company focused on the development ... patient has been enrolled in its Glucose Clamp Study. ... Texas Health Science Center at San Antonio ... under the supervision of Professor Ralph DeFronzo . ...
(Date:4/1/2015)... , April 1, 2015  Egalet Corporation ... specialty pharmaceutical company focused on developing, manufacturing and ... of an offering of $60.0 million aggregate principal ... (the "notes") in a private placement to qualified ... Securities Act of 1933, as amended (the "Act"). ...
Breaking Medicine Technology:International Isotopes Inc. Announces 2014 Year End Financial Results 2International Isotopes Inc. Announces 2014 Year End Financial Results 3International Isotopes Inc. Announces 2014 Year End Financial Results 4International Isotopes Inc. Announces 2014 Year End Financial Results 5International Isotopes Inc. Announces 2014 Year End Financial Results 6International Isotopes Inc. Announces 2014 Year End Financial Results 7Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin 2Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin 3Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 7
... NEW YORK, Sept. 13, 2011 IMMUNE ... based Therapeutics for the treatment of inflammatory diseases and ... M.D., Ph.D., to the position of Chief Medical Officer.  ... pivotal  role in the development of Bertilimumab, IMMUNE,s phase ...
... DIEGO, Sept. 13, 2011 Sequenom, Inc. (NASDAQ: ... solutions, today announced the Company,s participation at the UBS Global ... in New York City September 19-21, 2011. ... Development, will present on Monday, September 19, 2011 beginning at ...
Cached Medicine Technology:IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer 2IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer 3Sequenom Announces Participation at UBS Global Life Sciences Conference 2
... cool and your patient warm, with ... cooling system.,Designed around the Coanda Effect, ... localized air flow around your torso's ... during the heat and stress induced ...
... System is designed to provide excellent capture ... carotid stenting interventions. The ACCUNET is a ... utilizes rapid exchange technology so that the ... catheter manipulations. It is available in both ...
... The Precision PCx point of ... a whole-blood, patient-side testing system for ... use, the system provides fast, accurate ... hospital and laboratory information systems enables ...
Representing the next step in the evolution of point-of-care testing, the i-STAT 1 Analyzer uses one platform to perform glucose strip testing along with all i-STAT test cartridges....
Medicine Products: